Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M initial ask
On the same day Novartis erased the AveXis brand from the company, the ex-AveXis crew says their new gene therapy startup is ready for an IPO.
Taysha Gene Therapies has left enough bread crumbs for biotech sleuths to figure out that it’s going down this path. CEO RA Session II, who happily chatted to multiple reporters at launch, declined interviews for the recent Series B (and presumed crossover round); the biotech brought in a gene therapy program developed by its co-founder Steven Gray from Abeona; and days ago it tapped the ex-CMO and ex-CFO of AveXis to join the board, chaired by their former boss Sean Nolan.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.